Bolt Bio Picks Sunesis’s William Quinn as Chief Financial Officer

Bolt Biotherapeutics has appointed William Quinn to serve as its chief financial officer, the same position he held most recently at Sunesis Pharmaceuticals (NASDAQ: [[ticker:SNSS]]). Quinn’s experience also includes roles at Bullet Biotechnology and Jazz Pharmaceuticals (NASDAQ: [[ticker:JAZZ]]). Preclinical-stage Bolt Bio is developing a new class of cancer immunotherapies called immune-stimulating antibody conjugates. Last year, the
Redwood City, CA-based biotech raised $45 million in Series B financing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.